The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults

By Evans T.G.   Hasan M.   Galibert L.   Caron D.  

Vaccine, Vol. 21, Iss. 3, 2002-12 ,pp. : 322-329

Elsevier

Access to resources Recommend Favorite

A hepatitis B vaccine formulated with a novel adjuvant system

By Ambrosch F.   Wiedermann G.   Kundi M.   Leroux-Roels G.   Desombere I.   Garcon N.   Thiriart C.   Slaoui M.   Thoelen S.  

Vaccine, Vol. 18, Iss. 20, 2000-04 ,pp. : 2095-2101

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

By Thoelen S.   Van Damme P.   Mathei C.   Leroux-Roels G.   Desombere I.   Safary A.   Vandepapeliere P.   Slaoui M.   Meheus A.  

Vaccine, Vol. 16, Iss. 7, 1998-04 ,pp. : 708-714

Elsevier

Access to resources Recommend Favorite

Flt3 ligand and conjugation to IL-1 peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine

By Pisarev V.M.   Parajuli P.   Mosley R.L.   Chavez J.   Zimmerman D.   Winship D.   Talmadge J.E.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2358-2368

Elsevier

Access to resources Recommend Favorite

The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity

By Enioutina E.Y.   Visic D.   Daynes R.A.  

Vaccine, Vol. 18, Iss. 24, 2000-06 ,pp. : 2753-2767

Elsevier

Access to resources Recommend Favorite